Cardio-Oncology

Cardio-oncology for the 21st century: introduction.

Cardio-oncology: it takes two to translate.

As an emerging discipline focused on the cardiovascular care of cancer patients, cardio-oncology represents a novel platform for translational investigations. Toxic effects on the heart and vasculature caused by targeted cancer therapies can reveal insights into the biology of cardiovascular disease in humans. This phenomenon was first observed with trastuzumab, a monoclonal antibody that targe...

Cardio-Oncology: mechanisms of cardiovascular toxicity

The therapeutic options available to treat a wide range of malignancies are rapidly increasing. At the same time, the population being treated is aging with more cardiovascular risk factors, comorbid conditions, and associated poor cardiac reserve. Both traditional chemotherapeutic agents (for example, anthracyclines) and newer therapies (for example, targeted tyrosine kinase inhibitors and imm...

Cardio-oncology: a new medical issue

Due to the increasing number of long-term cancer survivors, the ageing of the population, as well as the increased incidence and prevalence of oncologic and cardiovascular diseases, the number of patients presenting oncologic and cardiologic co-morbidities are increasing. Accordingly, there is a rapidly growing need for a comprehensive and proficient management of patients in whom the two co-mo...

Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention

Due to the aging of the populations of developed countries and a common occurrence of risk factors, it is increasingly probable that a patient may have both cancer and cardiovascular disease. In addition, cytotoxic agents and targeted therapies used to treat cancer, including classic chemotherapeutic agents, monoclonal antibodies that target tyrosine kinase receptors, small molecule tyrosine ki...